Skip to contentS
Sigyn Therapeutics, Inc.
S
SIGYSigyn Therapeutics, Inc. Q1 2020 · 10-Q
Revenue$756.00$756.00−98.2% vs Q1 2019 Net Income-$153.21K-$153.21KN/M vs Q1 2019 EPS Diluted-$0.50-$0.50— vs Q1 2019 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sigyn Therapeutics, Inc. · CIK 1642159 · Engraved from SEC EDGAR
Operating Cash Flow-$4,261N/M Margins · derivedGross margin65.2%−12.5 pt vs Q1 2019
Operating margin-11961.8%−11555.4 pt vs Q1 2019
Net margin-20266.4%
ended Mar 31, 2020 · filed May 15, 2020 · 45 d after period end